China Chemical Regulatory China International Trade & Investment Government Affairs & Public Policy
ISLN:
909931467
Admitted:
Chinese National Bar
Law School:
Nanjing University in Nanjing, China, LL.B., 1993; Shanghai Academy of Social Science, LL.M., 1999; The George Washington University Law School, LL.M., 2002
License Records
Ying Huang
Address:
Washington, DC
License #:
0116010220 - Expired
Expiration Date:
Jun 30, 2000
Ying Huang
License #:
FMC09970 - Expired
Category:
Food Safety
Issued Date:
Jan 3, 2002
Expiration Date:
Jan 3, 2008
Type:
Certified Food Safety Mgr
Name / Title
Company / Classification
Phones & Addresses
Ying Huang Director
KINDERSIDE HOME HEALTH SERVICES, INC
20118 Standish Rd, San Antonio, TX 78258
Ying Huang Pharmacologist Cber/octgt/dcept/ptb
United States Health and Human Services
1101 Wootton Pkwy STE 600, Rockville, MD 20852
Ying Wei Huang
FUJIYAMA BROADVIEW HTS., INC
Ying Huang
Huang, Dr. Ying M Pediatrician
3444 Ellicott Ctr Dr, Ellicott City, MD 21043 (410)7502229
May 2011 to Jun 2013 Preschool Teacher, Quality Schools International, Ashgabat, TurkmenistanClifton Gunderson LLP Calverton, MD Jul 2005 to May 2007 Audit Associate
Education:
H. Smith School of Business, University of Maryland May 2005 B. S. in Accounting
Washington Eye Clinic 416 W Las Tunas Dr STE 304, San Gabriel, CA 91776 (626)5882518 (phone)
Education:
Medical School Louisiana State University School of Medicine at New Orleans Graduated: 1998
Procedures:
Lens and Cataract Procedures
Conditions:
Cataract Glaucoma Keratitis Retinal Detachments
Languages:
Chinese English
Description:
Dr. Huang graduated from the Louisiana State University School of Medicine at New Orleans in 1998. He works in San Gabriel, CA and specializes in Ophthalmology. Dr. Huang is affiliated with San Gabriel Valley Medical Center.
Reference: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial by Feng-Cai Zhu, Xu-Hua Guan, Yu-Hua Li, Jian-Ying Huang, Tao Jiang, Li-Hua Hou, Jing-Xin Li, Be
Date: Jul 20, 2020
Category: More news
Source: Google
Gilead Sciences, Inc Stock May Be in For a Rally Ahead of EASL
According to Merrill Lynch analyst Ying Huang who has also commented on the published abstracts Gileads 24-week sof/vel combo drug with or without ribavirin delivered a retreatment option for patients who failed initial treatment with the same combo med for 8-12 weeks. An 8-week triple combinat
Date: Apr 01, 2016
Category: Business
Source: Google
Cost of Gilead's hepatitis C pill, Sovaldi, spurs revolt
"It's just the sheer number of patients who have the disease. Multiply that number by that price," said Ying Huang, a senior biotechnology analyst at Barclays, whose clients include Gilead. "All of a sudden, you get a big number."
approved in 100 countries for kidney cancer and liver cancer, are split between Bayer and Onyx. The drug had sales of roughly $900 million last year. An expanded approval for thyroid cancer could result in an additional $300 million in peak global sales annually, said Ying Huang, a Barclays analyst.
Date: Jun 02, 2013
Category: Health
Source: Google
GlaxoSmithKline extends tender offer for Human Genome Sciences
"We continue to believe the most likely outcome will be a slightly higher bid from GSK, with no white knights coming to the table with a substantially higher bid," said Ying Huang and Brian Bourdot at Barclays Capital.